Dose Ranging Study With LT, Monotherapy, PPAR

Phase 2/3 Completed 1260 enrolled Bristol-Myers Squibb

RandomizedParallel-groupDouble-blindTreatment

Summary

A Randomized, Double-Blind, Dose-Ranging, Dose Comparison-Controlled Trial to Determine the Safety and Efficacy of BMS-298585 in Subjects with Type 2 Diabetes

Timeline

Start: 2002-05
Primary completion: 2006-06
Completion: 2006-06

Publications

Rubin CJ, Viraswami-Appanna K, Fiedorek FT. Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes. Diab Vasc Dis Res. 2009 Jul;6(3):205-15. doi: 10.1177/1479164109336048.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Muraglitazar	Small molecule	0.5 mg	—
Subject	Muraglitazar	Small molecule	1.5 mg	—
Subject	Muraglitazar	Small molecule	5 mg	—
Subject	Muraglitazar	Small molecule	10 mg	—
Subject	Muraglitazar	Small molecule	20 mg	—

Dose Ranging Study With LT, Monotherapy, PPAR

Summary

Timeline

Publications

Drugs

Indications